Sunday 18 October 2026
Export ARMP’s income statement to Excel — free account
Armata Pharmaceuticals, Inc.
ARMP Healthcare Biotechnology
Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 548.9%, free cash flow fell 18.0% and total debt rose 152.4%, each against the same quarter a year earlier.
3.37
0.28
+9.06%
Follow ARMP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
42.96 | 71.91 | 46.41 | 21.36 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(27.48) | (64.70) | (34.10) | (25.12) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
89.79 | 162.11 | 123.75 | 47.39 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(19.58) | (35.19) | (23.56) | (8.87) | |
EV/FCF |
(19.29) | (34.46) | (23.07) | (8.73) | |
Quick Ratio |
0.11 | 0.52 | 1.02 | 0.11 | |
Current Ratio |
0.11 | 0.64 | 1.19 | 0.12 | |
Net Debt/EBITDA |
(26.70) | (40.60) | (18.52) | (17.76) | |
Debt/Assets |
315.18% | 491.26% | 334.18% | 163.46% | |
Debt/Equity |
(1.23) | (1.10) | (1.18) | (1.53) | |
Asset Turnover |
0.06 | 0.07 | 0.06 | 0.05 | |
Operating CF/Net income |
(0.12) | 0.05 | 0.05 | 0.16 | |
Capex/Depreciation |
(0.03) | (0.14) | (0.12) | (0.65) | |
Interest Coverage |
(1.55) | (1.58) | (2.86) | (1.79) | |
Research and Development Expense of Revenue |
302.23% | 774.52% | 559.45% | 502.50% | |
Selling, General and Administrative Expense of Revenue |
208.61% | 438.91% | 315.76% | 268.42% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.05 | 0.04 | |
Share Based Compensation of Revenue |
135.10% | 136.25% | 58.25% | 53.67% | |
Graham Net Nets |
(1.23) | (1.00) | (1.25) | (1.56) | |
Graham Number |
27.42 | 38.64 | 25.52 | 8.79 | |
Earnings Yield |
(81.94%) | (75.98%) | (76.43%) | (43.62%) | |
Free Cash Flow Yield |
(10.83%) | (6.54%) | (11.56%) | (25.41%) | |
Revenue per Share |
0.07 | 0.02 | 0.03 | 0.03 | |
Operating CF per Share |
(0.24) | (0.16) | (0.18) | (0.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.24) | (0.16) | (0.19) | (0.13) | |
Cash per Share |
0.65 | 0.13 | 0.24 | 0.41 | |
Shareholders Equity per Share |
(6.29) | (8.53) | (6.03) | (2.64) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(6.29) | (8.53) | (6.03) | (2.64) | |
Free Cash Flow |
(8.68) | (5.84) | (6.73) | (4.54) | |
Working Capital |
(223.04) | (3.28) | 1.72 | (123.02) | |
Capital Expenditures |
(0.02) | (0.06) | (0.05) | (0.24) | |
Net Current Asset Value |
(293.97) | (375.44) | (284.81) | (168.17) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.08 | 0.05 | 0.21 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.35 | 0.14 | 0.61 | 1.49 | |
Average Payables |
1.70 | 1.53 | 1.88 | 2.86 | |
Average Assets |
85.37 | 78.53 | 81.66 | 93.88 | |
Average Common Equity |
(150.34) | (182.68) | (133.31) | (73.28) |
Columns are period end dates